Last reviewed · How we verify
Carbamazepin
Carbamazepin is a Small molecule drug developed by Enanta Pharmaceuticals, Inc. It is currently FDA-approved for Bipolar affective disorder, current episode manic, Bipolar disorder in remission, Epilepsy. Also known as: tegretol, bamgetol.
Carbamazepine is a small molecule that acts as a blocker of the sodium channel alpha subunit. It is used to treat conditions such as epilepsy and bipolar disorder, and is available in controlled-release formulations.
At a glance
| Generic name | Carbamazepin |
|---|---|
| Also known as | tegretol, bamgetol |
| Sponsor | Enanta Pharmaceuticals, Inc |
| Target | Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Bipolar affective disorder, current episode manic
- Bipolar disorder in remission
- Epilepsy
- Epilepsy characterized by intractable complex partial seizures
- Glossopharyngeal neuralgia
- Lennox-Gastaut syndrome
- Localization-related epilepsy
- Mixed Epilepsy
- Mixed bipolar I disorder
- Simple partial seizure
- Tonic-clonic epilepsy
- Tonic-clonic seizure
- Trigeminal neuralgia
Common side effects
- Dizziness
- Drowsiness
- Unsteadiness
- Nausea
- Vomiting
- Headache
- Fatigue
- Blurred vision
- Disturbances of coordination
- Confusion
- Gastric distress
- Abdominal pain
Serious adverse events
- Aplastic anemia
- Stevens-Johnson Syndrome (SJS)
- Toxic Epidermal Necrolysis (TEN)
- Agranulocytosis
- Hepatic failure
- Congestive heart failure
- Myocardial infarction
- Pulmonary embolism
- Neuroleptic malignant syndrome
- Pancreatitis
Key clinical trials
- A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144 (PHASE1)
- Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity (EARLY_PHASE1)
- A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012) (PHASE1)
- A Study of Ponesimod in Healthy Adult Participants (PHASE1)
- A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants (PHASE1)
- Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia (PHASE4)
- A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants (PHASE1)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carbamazepin CI brief — competitive landscape report
- Carbamazepin updates RSS · CI watch RSS
- Enanta Pharmaceuticals, Inc portfolio CI
Frequently asked questions about Carbamazepin
What is Carbamazepin?
Carbamazepin is a Small molecule drug developed by Enanta Pharmaceuticals, Inc, indicated for Bipolar affective disorder, current episode manic, Bipolar disorder in remission, Epilepsy.
What is Carbamazepin used for?
Carbamazepin is indicated for Bipolar affective disorder, current episode manic, Bipolar disorder in remission, Epilepsy, Epilepsy characterized by intractable complex partial seizures, Glossopharyngeal neuralgia.
Who makes Carbamazepin?
Carbamazepin is developed and marketed by Enanta Pharmaceuticals, Inc (see full Enanta Pharmaceuticals, Inc pipeline at /company/enanta-pharmaceuticals-inc).
Is Carbamazepin also known as anything else?
Carbamazepin is also known as tegretol, bamgetol.
What development phase is Carbamazepin in?
Carbamazepin is FDA-approved (marketed).
What are the side effects of Carbamazepin?
Common side effects of Carbamazepin include Dizziness, Drowsiness, Unsteadiness, Nausea, Vomiting, Headache. Serious adverse events: Aplastic anemia, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Agranulocytosis.
What does Carbamazepin target?
Carbamazepin targets Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4.
Related
- Target: All drugs targeting Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4
- Manufacturer: Enanta Pharmaceuticals, Inc — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Bipolar affective disorder, current episode manic
- Indication: Drugs for Bipolar disorder in remission
- Indication: Drugs for Epilepsy
- Also known as: tegretol, bamgetol
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing